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Background: Treatment with atorvastatin (ATO) or dietary control has been demonstrated to benefit patients with
non-alcoholic fatty liver disease (NAFLD) and hyperlipidemia. However, little is known on whether combination of
dietary control and ATO treatment could enhance the therapeutic effect.
Methods: We employed a rat model of NAFLD to examine the therapeutic efficacy of dietary control and/or ATO
treatment. Sprague-Dawley rats were fed with normal chow diet as normal controls or with high fat diet (HFD) for
12 weeks to establish NAFLD. The NAFLD rats were randomized and continually fed with HFD, with normal chow
diet, with HFD and treated with 30 mg/kg of ATO or with normal chow diet and treated with the same dose of
ATO for 8 weeks. Subsequently, the rats were sacrificed and the serum lipids, aminotranferase, hepatic lipids, and
liver pathology were characterized. The relative levels of fatty acid synthesis and b-oxidation gene expression in
hepatic tissues were measured by quantitative real-time polymerase chain reaction (qRT-PCR). Hepatic expression of
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase was determined by Western blot assay.
Results: While continual feeding with HFD deteriorated NAFLD and hyperlipidemia, treatment with dietary control,
ATO or ATO with dietary control effectively improved serum and liver lipid metabolism and liver function. In
comparison with ATO treatment, dietary control or combined with ATO treatment significantly reduced the liver weight
and attenuated the HFD-induced hyperlipidemia and liver steatosis in rats. Compared to ATO treatment or dietary
control, combination of ATO and dietary control significantly reduced the levels of serum total cholesterol and low
density lipoprotein cholesterol (LDL-C). However, the combination therapy did not significantly improve triglyceride and
free fatty acid metabolism, hepatic steatosis, and liver function, as compared with dietary control alone.
Conclusions: ATO treatment effectively improved NAFLD-related hyperlipidemia and inhibited liver steatosis,
accompanied by modulating the expression of genes for regulating lipid metabolism. ATO enhanced the effect of
dietary control on reducing the levels of serum total cholesterol and LDL-C, but not triglyceride, free fatty acid and
hepatic steatosis in HFD-induced fatty liver and hyperlipidemia in rats.
Background
Non-alcoholic fatty liver disease (NAFLD) is a common
hepatic disease, and pathologically, it can display as sim-
ple steatosis, non-alcoholic steatohepatitis (NASH), and
eventually progress to cirrhosis, an end-stage liver disease
[1]. The prevalence of NAFLD ranges from 6% to 14% in
different populations [2]. The median prevalence of ultra-
sonographic steatosis in Chinese populations is about
10%, but varies from 1% to more than 30%[3]. Notably,
1%-5% of patients with simple steatosis can eventually
develop actual cirrhosis, and 10% to 15% of patients with
NASH can progress to cirrhosis and even to hepatocellu-
lar carcinoma[4,5].
The pathogenic process of NAFLD is not well under-
stood and effective therapy for NAFLD has not been
established. Currently, treatment for NAFLD is generally
dependent on gradual loss of body weight and change in
lifestyle. However, these strategies have poor compliance
in many patients, and whether these strategies are still
beneficial for patients with advanced disease is unknown.
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therapeutic reagents. Insulin receptor sensitizing agents
and antioxidants have been tested for the treatment of
NAFLD[6]. However, their therapeutic efficacy and clinical
safety remain to be established. Recently, several studies
reveal that treatment with atorvastatin (ATO) is effective
and safe for patients with NAFLD or NASH with hyperli-
pidemia[7,8]. However, whether the efficacy of ATO treat-
ment is better than dietary control and whether ATO can
synergize with dietary control to enhance the therapeutic
efficacy for NAFLD have not been explored.
This study aimed at examining the therapeutic efficacy
of dietary control combined with ATO treatment in a
rat model of NAFLD with hyperlipidemia and at explor-
ing potential mechanism(s) underlying the therapeutic
effect of dietary control and/or ATO treatment on inhi-
biting the high fat diet (HFD)-induced hyperlipidemia
and liver steatosis.
Results
Establishment of rat model of NAFLD
Male SD rats were fed with HFD or normal chow diet
for 12 weeks, and six rats were randomly chosen from
each group for liver histopathology. Hepatocytes in the
HFD-fed rat liver tissues displayed different sizes of
lipid droplets in the cytoplasm (Figure 1A). However,
the fatty liver disease-related characteristic was absent
in the liver tissues of normal control rats (Figure 1B).
Hence, feeding with HFD for 12 weeks induced
NAFLD in rats.
Dietary control and ATO treatment reduced the liver
weight in NAFLD rats
Following treatment with ATO for 8 weeks, the body
and liver weights as well as the ratios of liver to body
weights in each group of rats were measured (Table 1).
T h e r ew a sn os i g n i f i c a n td i f f e r e n c ei nt h eb o d yw e i g h t
among these groups of rats (p > 0.05). In contrast, the
liver weight and the ratios of liver to body weights in
the model group were significantly higher than that of
other groups (p < 0.05 for all). The liver weights and the
ratios of liver to body weights between the DC and
D C Ag r o u p sw e r en o ts i g n i f i c a n t l yd i f f e r e n t( p >0 . 0 5 ) ,
but they were significantly lower than that of the ATO
group (p < 0.05, p < 0.05). Apparently, continual feeding
with HFD deteriorated the hepatic steatosis and predo-
minately increased the liver weights, while dietary con-
trol by feeding with normal chow diet or combined with
ATO treatment inhibited the progression of hepatic
steatosis and the gain in liver weights in NAFLD rats.
Dietary control and ATO treatment attenuated the HFD-
induced hepatic steatosis
After being stained with H&E, the degrees of hepatic
steatosis were examined. While there was no obvious
steatosis in the liver of the normal group of rats,
Figure 1 Histological analysis of the rat livers. Male SD rats were fed with normal chow diet (normal control) or with HFD for 12 weeks, and their
liver tissue sections were stained with H&E staining, followed by examining under a light microscope. Data shown are representative images
(magnification 40x) of normal control and NAFLD rats (n = 6 per group) from two separate experiments. (A) HFD-fed NAFLD rats; (B) Normal control rats
Table 1 The body weights, liver weights and the ratios of
liver to body weights in rats
Group Liver weight (g) Body weight (g) Liver/Body (%)
Normal 12.48 ± 0.91 547.72 ± 25.95 2.28 ± 0.12
Model 27.00 ± 3.56
† 542.14 ± 34.40 4.98 ± 0.58
†
DC 13.80 ± 1.88*
‡ 509.11 ± 48.39 2.71 ± 0.30*
‡
DCA 12.81 ± 1.16*
‡ 520.23 ± 28.97 2.46 ± 0.19*
‡
ATO 20.92 ± 2.45* 512.11 ± 51.87 4.11 ± 0.56*
Normal: The rats received normal chow diets throughout the experimental
period; Model: The rats fed with high fat diet (HFD) continually for 20 weeks.
DC: Dietary control (rats were fed with HFD for 12 weeks, and then fed with
normal diet for 8 weeks); ATO (atorvastatin): Treatment with ATO alone (rats
were fed with HFD for 12 weeks, and then fed with HFD and atorvastatin for
8 weeks); DCA: Dietary control combined with ATO treatment (rats were fed
with HFD for 12 weeks, and then normal diet with atorvastatin for 8 weeks).
Values are mean ± SD, n = 8 per group.
†p < 0.05 versus the normal group;
*p < 0.05 versus the model group;
‡ p < 0.05 versus the ATO group.
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group rats (Figure 2). The area of hepatic steatosis in the
DC and DCA groups decreased remarkably when com-
pared with that in the model group, however, there was
no significant difference in the score of liver steatosis
between the DC and DCA groups. Further analysis
revealed that the score of hepatic steatosis in the ATO
group was significantly reduced, as compared with that
in the model group, however, they remained significantly
higher than that of the DC or DCA group (Figure 3).
Similarly, the levels of hepatic TC and TG in the
model group were significantly higher than that of the
normal control, DC and DCA groups, but there was no
o b v i o u sd i f f e r e n c eb e t w e e nt h eD Ca n dD C Ag r o u p s .
Figure 2 Pathogenic degrees of the rat livers. Histological analysis of the rat livers. NAFLD rats were randomized and fed with HFD (Model),
with HFD and treated p.o with 30 mg/Kg body weight of ATO daily (ATO), with normal chow diet (DC), with normal chow diet and treated
with the same dose of ATO (DCA) for 8 weeks. Healthy rats were fed continually with normal chow diet and used as normal controls (Normal).
Their liver tissue sections were stained with H&E and examined under a light microscope. Data shown are representative images (magnification
40x) of each group (n = 8 per group) from four independent experiments and control and experimental rats were analyzed simultaneously. (a)
Normal control group; (b) The model group; (c) The DC group; (d) The DCA group; and (e) The ATO group.
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significantly higher than that of the DC and DCA
groups (Table 2).
To determine whether dietary control and ATO treat-
ment could mitigate the HFD-induced liver injury, the
concentrations of serum ALT and AST in different
groups of rats were examined. The concentrations of
serum ALT and AST in the model group were signifi-
cantly higher than that of the normal control, DC, DCA
and ATO groups. While the levels of serum ALT and
AST were comparable between the DC and DCA
groups. The level of serum AST, but not ALT, in the
ATO group were significantly higher than that of the
DC and DCA groups (Table 2).
Dietary control and ATO treatment improved serum lipid
profiles
As shown in Table 3, there was no significant difference
in the level of serum HDL-C among these groups of
rats. The concentrations of serum TC, TG, and LDL-C
in the model group were significantly higher than those
of other groups (p =0 . 0 0 2 ,p = 0.001, and p =0 . 0 0 2
respectively). There was no significant difference in the
levels of serum TC, TG, and LDL-C between the DC
and ATO group rats. Interestingly, the levels of serum
TC and LDL-C, but not TG in the DCA group was sig-
nificantly lower than those of the DC and ATO. Finally,
analysis of serum FFA revealed that the levels of serum
FFA in the model group were significantly higher than
that of other groups, while no significant difference was
detected in the normal control, DC, DCA, and ATO
groups of rats. These data indicated that combination of
dietary control and ATO treatment improved lipid pro-
files in the HFD-fed rats.
Effect of dietary control and ATO treatment on the
transcription of the PPARa and SREBP-1c-related genes in
the liver
To explore the mechanisms underlying the effect of
dietary control and ATO treatment, the relative levels of
PPARa and SREBP-1c-related gene transcripts in the
liver were determined by qRT-PCR. The relative levels
of SREPB-1c and its target FAS and ACC mRNA tran-
scripts in the model group were 4-8 fold higher than
Figure 3 Scores of hepatic steatosis of rat livers. The scores were determined, according to the the percentage of hepatocytes containing
lipid droplets. Data are expressed as mean ± SD of each group (n = 8 per group) and determined by a pathologist in a blinded fashion.
††p <
0.01 versus the normal group; *p < 0.05 versus the model group;
‡ p < 0.05 versus the ATO group.
Table 2 The levels of serum animotransferases and hepatic lipids in rats
Group Serum ALT (U/L) Serum AST (U/L) Hepatic TC (mg/g) Hepatic TG (mg/g)
Normal 30.30 ± 4.79 69.60 ± 7.78 0.94 ± 0.21 1.61 ± 0.82
Model 79.30 ± 22.23
†† 135.20 ± 26.52
†† 6.33 ± 1.59
†† 3.51 ± 0.77
††
DC 42.70 ± 12.72** 79.10 ± 13.4**
‡ 4.19 ± 1.15**
‡ 2.29 ± 0.95**
DCA 40.60 ± 5.50** 73.6 ± 11.26**
‡ 4.26 ± 1.02**
‡ 2.10 ± 0.79**
ATO 43.40 ± 7.41** 100.70 ± 6.04* 4.90 ± 0.27 2.53 ± 0.65*
Values are mean ± SD, n = 8 per group. DC: dietary control; ATO: atorvastatin; DCA, dietary control combined with ATO.
††p < 0.01 versus the the normal group;
**p < 0.01 versus the model group; *p < 0.05 versus the model group;
‡p < 0.05 versus the ATO group.
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trast, the relative levels of those transcripts in the DC,
DCA, and ATO groups were reduced by 25-50%, as
compared with that in the model group, although they
were still significantly higher than that of the normal
control group. While there was no significant difference
in the relative levels of FAS and ACC among the DC,
DCA, and ATO groups, the relative levels of SREBP-1c
mRNA transcripts in the ATO group were higher than
that of the DC and DCA groups (p < 0.05). Apparently,
dietary control and ATO treatment inhibited the HFD-
induced transcription of these genes in rats. Further
analysis revealed that the relative levels of PPARa
mRNA transcripts, but not CPT-1 and ACO, in HFD-
fed rats were significantly lower than that in the normal
controls(p < 0.01) (Figure 4B). Furthermore, the relative
levels of PPARa mRNA transcripts in the model group
were significantly lower than that of the DC, DCA, and
ATO groups of rats (p <0 . 0 5 ,p < 0.05, p < 0.05), while
the relative levels of PPARa mRNA transcripts in the
ATO group were also significantly lower than that of
t h eD Ca n dD C Ag r o u p so fr a t s( p < 0.05, p < 0.05).
These data indicated that feeding with HFD significantly
inhibited the PPARa transcription, but did not affect
the expression of other lipid-oxidative genes tested.
Dietary control and ATO treatment appeared to antago-
nize the effect of HFD in rats.
Effect of dietary control and ATO treatment on the
expression of HMG-CoA reductase in the liver
HMG-CoA reductase is most abundantly expressed in
the liver, and plays a central role in the regulation of
plasma cholesterol concentration[9]. ATO is an inhibi-
tior of the HMG-CoA reductase and can inhibit choles-
terol synthesis. As shown in Figure 5, the relative
expression of HMG-CoA reductase in the liver of the
model of group rats was 3.9-fold higher than that of the
normal control (p = 0.001). However, its expression was
significantly reduced by 48%(p < 0.05), 73% (p < 0.01)
and 52% (p < 0.05) in the DC, DCA and ATO group of
rats, respectively, More importantly, the relative levels of
HMG-CoA reductase in the livers of DCA group of rats
were significantly lower than that of the ATO groups of
rats (p < 0.05). Moreover, the levels of HMG-CoA
reductase in DCA group of rats decreased more signifi-
cantly than those in DC.
Discussion
NAFLD is a common chronic liver disease worldwide
and its incidence is increasing in developed countries
[10]. Over-consumption of high calories of foods, parti-
cularly HFD, is crucial for the development of NASH
and NAFLD. Conceivably, control of diet is important
for the prevention and intervention of NASH. Dietary
control and lifestyle modification appear to be an effec-
tive therapeutic strategy for intervention of NAFLD in
individuals with obese and insulin resistance [11,12].
Recent studies have shown that treatment with ATO
also benefits patients with NASH and NAFLD[7,8]. In
this study, we compared the efficacy of dietary control
and/or ATO treatment on the HFD-induced hepatic
steatosis and hyperlipidemia in rats. We found that diet-
ary control or combined with ATO treatment for 8
weeks significantly inhibited the HFD-induced liver
weights and reduced the ratios of liver to body weights
in the NAFLD rats. However, we did not observe signifi-
cant difference in the body weights among those groups
of rats, consistent with previous reports in this model of
rats[13,14]. The reason may be that a high fat diet may
induce anorexia in rats [15,16]. Furthermore, dietary
control or combined with ATO treatment mitigated the
HFD-induced hepatic steatosis, which was associated
with the improvement of liver and systemic lipid profiles
and function, leading to reduction in the severity of
hyperlipidemia in NAFLD rats. Therefore, our data sup-
port the notion that dietary control and personal life-
style modifications are critical for the control of
hyperlipidemia and associated NAFLD. However,
whether dietary control for a longer period could pre-
vent the development of NAFLD-related liver fibrosis
and dietary control could improve lipid metabolism in
advanced NAFLD, remain to be further investigated.
Surprisingly, treatment with ATO alone only had mild
or moderate benefits for the NAFLD rats, while combi-
nation of ATO treatment with dietary control did not
enhance the effect of dietary control on reducing the
Table 3 The levels of serum lipids in rats
Group TC (mmol/L) TG (mmol/L) LDL-C(mmol/L) HDL-C(mmol/L) FFA(μmmol/L)
Normal 1.45 ± 0.14 0.68 ± 0.14 0.24 ± 0.07 0.82 ± 0.14 50.14 ± 11.10
Model 4.36 ± 1.70
†† 0.91 ± 0.10
†† 3.82 ± 1.88
†† 0.83 ± 0.18 63.55 ± 13.68
†
DC 2.15 ± 0.23** 0.70 ± 0.22** 1.28 ± 0.08** 0.82 ± 0.16 42.66 ± 11.89*
DCA 1.47 ± 0.19**
‡ 0.72 ± 0.13** 0.33 ± 0.10**
‡ 0.83 ± 0.16 45.33 ± 9.76*
ATO 2.35 ± 0.40* 0.75 ± 0.26** 1.30 ± 0.44** 0.82 ± 0.13 50.40 ± 13.38*
DC: dietary control; ATO: atorvastatin; DCA, dietary control combined with ATO. Values are mean ± SD, n = 8.
††p < 0.01 versus the normal group; **p < 0.01
versus the model group; *p < 0.05 versus to model group;
‡p < 0.05 versus the ATO group.
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Figure 4 The expression of lipid metabolic regulators in the liver. (A) The expression of hepatic SREBP-1c and related genes. The relative
levels of hepatic SREBP-1c, FAS, and ACC mRNA transcripts to control GAPDH were determined by quantitative RT-PCR. Data are expressed as
mean ± SD of each group (n = 8 per group) from three independent experiments and control, and experimental rat livers were simultaneously
analyzed. The value of the normal control group was designated as 1 for each gene. (B) The expression of PPARa and related genes. The relative
levels of PPARa, CPT-1, and ACO mRNA transcripts to control GAPDH were determined by quantitative RT-PCR. The value of the normal control
group was designated as 1 for each gene.
††p < 0.01 versus the normal group; *p < 0.05 versus the model group;
‡p < 0.05 versus the ATO
group.
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acid, liver injury, and hepatic steatosis in our experimen-
tal system. The present study revealed that dietary con-
trol remained a basic therapy for the NAFLD, and to
some extent, this was similar to a previous report that
antioxidant (alpha-tocopherol plus ascorbic acid) does
not increase the efficacy of lifestyle intervention alone in
NAFLD model [17]. Apparently, treatment with ATO or
antioxidant does not synergize with dietary control in
inhibiting HFD-induced liver damage. Our findings were
different from that the findings by Martin-Castillo et al,
who found that the combination of ATO treatment with
a standard diet did reduce the scores of NAFLD activity
more [18]. The difference between our and their find-
ings may be due to different models studied.
Previous studies have shown that the transcription fac-
tors, SREBP-1c, the PPARa, and the expression of their
targeting genes, such as the FAS, ACC, CPT-1, and
ACO, are crucial for the development of NAFLD. The
SREBP-1c can modulate the expression of a large num-
ber of genes involved in the uptake of lipoproteins, the
synthesis of cholesterol, TG, and VLDL[19]. The PPARa
regulates the expression of the genes involved in mito-
chondrial and liver fatty acid b-oxidation[20]. Down-reg-
ulation and deficient expression of PPARa are
associated with the development of NASH, and treat-
ment with agonist for PPARa prevents and inhibits the
development of NAFLD[21,22]. Consistently, we found
that HFD increased the transcription of SREBP-1c, FAS,
and ACC, but decreased the levels of hepatic PPARa
mRNA transcripts in the rats while dietary control and
treatment with ATO down-regulated the expression of
hepatic SREBP-1c and its targeting genes, but up-regu-
lated the transcription of PPARa mRNA in the rats.
Our data were consistent with previous findings that
treatment with ATO up-regulated the expression of
PPARa, liver fatty acid b-oxidation, and reduced the
liver TG in rats [23,24]. Therefore, the down-regulated
expression of SREBP-1c and its targeting genes that
inhibiting lipogenesis, and up-regulated expression of
PPARa that promoting lipid metabolism, may contri-
bute to the therapeutic effect of dietary control and
ATO treatment on the HFD-induced hyperlipidemia





Figure 5 Western blot analysis of hepatic HMG-CoA reductase in rats. The relative levels of hepatic HMG-CoA reductase to control GAPDH
in different groups of rats were determined by Western blot assays using specific antibodies. (A) Western blot analysis. Data shown are
representative images. (B) Quantitative analysis. Data are expressed as means ± SD of each group, (n = 8) from three separate experiments.
††p <
0.01 versus the normal group; *p < 0.05 versus the model group; **p < 0.01 versus the model group;
‡p < 0.05 versus the ATO group.
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and is crucial for sterol synthesis, which is negatively
regulated by binding to Insig. When plasma sterol levels
are low, SREBP is released by the cleavage of a mem-
brane-bound precursor protein and migrates to the
nucleus, where it binds to the sterol regulatory element
(SRE) and activates the transcription of genes for HMG-
CoA reductase and other enzymes involved in the cho-
lesterol synthesis. On the other hand, elevated levels of
plasma cholesterol promote the proteolytic cleavage of
SREBP from the membrane ceases and protein degrada-
tion in the nuclei[25,26]. We found that treatment with
ATO at a dose that has been demonstrated to be effec-
tive and safe for the control of hyperlipidemia could sig-
nificantly reduce the hepatic expression of HMG-CoA
reductase. More importantly, the relative levels of hepa-
tic HMG-CoA reductase expression in the DCA group
were significantly lower than that of the ATO and DA
groups of rats. The significantly reduced levels of hepa-
tic HMG-CoA reductase may be associated with the
lower levels of serum TC and LDL-C in the DCA group
of rats. Our data indicate that combination of ATO
treatment with dietary control may be an effective thera-
peutic strategy for the treatment of HFD-induced
hypercholesterolemia and related cardiovascular disease.
Conclusions
Our data indicated that treatment with ATO had mild
or moderate effect on inhibiting the progression of
NAFLD and hyerlipidemia in HFD-fed rats. ATO treat-
ment enhanced the effect of dietary control in reducing
the levels of serum TC and LDL-C, but not TG, FFA,
hepatic lipids and liver steatosis in HFD-fed rats.
Materials and methods
Animals and treatment
Fifty-two male Sprague-Dawley (SD) rats at 6 weeks of
age and weighing 180-220 g were from the Experimental
Animal Center of Guangdong Province (China), and
housed in a specific pathogen free facility maintained at
a cycle of 12 h light/dark and a constant temperature of
22°C~26°C, and a relative humidity of 65 ± 15%.
The rats were randomized and fed with normal chow
diet (n = 14, 10% of calories derived from fat; D12450B)
or high fat diet (HFD, n = 38, 60% of calories derived
from fat; D12492) for 12 weeks to induce NAFLD with
hyperlipidemia, as described previously [11,12]. At the
end of the 12-week induction, six rats from normal
chow diet group or HFD group were randomly chosen
and sacrificed. Their liver histopathology was analyzed
for the development of NAFLD. Subsequently, the 32
HFD-fed rats were further randomized into four groups
and continually fed with HFD (model group), with HFD
and treated P.O with 30 mg/kg of ATO (Sigma-Aldrich,
S t .L o u i s ,M O )( A T Og r o u p ) ,w i t hn o r m a lc h o wd i e t
(dietary control, DC group), or with normal chow diet
and treated with the same dose of ATO (combination of
dietary control with ATO, DCA group) daily for 8
weeks, respectively. Rats fed with normal chow diet
without exposure to HFD were used as the normal
controls.
At the end of dietary control and ATO treatment, the
rats were fasted for 12 hours and sacrificed. Their blood
samples were collected from the abdominal aorta, and
their sera were prepared by centrifugation, frozen, and
stored at -20°C until analysis. Their livers were frozen in
liquid nitrogen and stored at -80°C until gene expression
analysis. A portion of the liver from individual rats was
fixed overnight in 10% formalin for histological analysis.
Two additional samples of liver tissues (150 mg) were
stored at -80°C for Westernblot analysis assay and liver
lipids measurement. The experimental protocols were
approved by the Animal Care and Protection Committee
of Sun Yat-Sen University.
Analyses of serum lipids and transaminases
The concentrations of serum total cholesterol (TC), tri-
glyceride(TG), low density lipoprotein-cholesterol (LDL-
C), high density lipoprotein-cholesterol (HDL-C), aspar-
tate aminotransferase (AST), and alanine aminotransfer-
ase (ALT) were measured using the corresponding
commercial enzyme kits (Biosino, Beijing, China) on an
automatic biochemistry analyzer (Olympus AU600,
Tokyo, Japan). The levels of serum free fatty acid (FFA)
were assayed using a commercial kit, according to the
manufacturer’s instruction (R&D, Minneapolis, USA).
Liver triglyceride and cholesterol
Total lipids were extracted from 100 mg of liver tissues,
according to the method of Bligh and Dyer [27]. Briefly,
total lipids in liver tissues were extracted with chloro-
form-methanol (2:1). After evaporation overnight, the
extracted lipids were re-suspended in 10% triton and
isopropanol, and quantified using a commercial enzyme
assay kit (Biosino, Beijing, China) on an automatic bio-
chemistry analyzer.
RNA extraction and quantitative Real-Time Polymerase
Chain Reaction (qRT-PCR)
The relative levels of sterol regulatory element binding
protein 1c (SREBP-1c), fatty acid synthase (FAS), acetyl-
CoA carboxylase (ACC), peroxisome proliferator-acti-
vated receptor alpha (PPARa), acyl-CoA oxidase (ACO),
carnitine palmitoyltransferase-1 (CPT-1), and mRNA
transcripts to control glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) were determined by qRT-PCR.
Briefly, total RNA was extracted from individual liver
samples using Trizol reagent (Invitrogen, USA) and
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script kit, according to the manufacturer’sp r o t o c o l
(Genecopoeia, USA). Subsequently, the cDNA was used
as the template for characterization of the relative levels
of mRNA transcripts of individual target genes to con-
trol GADPH by qRT-PCR using SYBR Green fluores-
cence and the specific primers on an iCycler
thermocycler (BioRad Hercules, CA). The sequences of
the primers were synthesized, according to the previous
studies[28,29] and are shown in Table 4. The PCR reac-
tions were performed in duplicate at 95°C for 10 min
and subjected to 35 cycles of 95°C for 10 s, 60°C for 20
s, and 72°C for 15 s, followed by extension at 72°C for
10 min. The values of threshold cycle (Ct) were deter-
mined by automated threshold analysis using Opticon
Monitor 3.1 software. The relative levels of each gene
expression were determined by the 2
-ΔΔCt method.
Western blot analysis of HMG-CoA reductase
The expression of hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase
in hepatic tissue was determined by Western blot
assay. Briefly, frozen liver samples were homogenized in
RIPA lysis buffer containing protease and phosphatase
inhibitors. After centrifuged, the protein contents in the
lysates were measured using a BCA protein assay kit
(Beyotime, China). Individual lysates (30 ug) were sepa-
rated by 10% SDS-PAGE and electrotransferred to poly-
vinylidene difluoride (PVDF) membranes. After being
blocked with 5% non-fat milk in Tris-buffered saline
with 0.1% Tween-20 (TBST, 25 mM Tris, pH 8.0, 137
mM NaCl, 2.7 mM KCl, and 0.1% Tween-20) at room
temperature for 60 min, the membranes were incubated
with anti- HMG-CoA reductase or anti-GAPDH antibo-
dies (Santa Cruze Biotechnology, Santa Cruze, USA)
overnight at 4°C. The bound antibodies were detected
with horseradish peroxidase (HRP)-conjugated goat
anti-rabbit IgG antibodies (Santa Cruze Biotechnology)
and visualized using the enhanced chemiluminescence
(ECL, Pierce, Rockford, IL) system and exposed to X-ray
film (Kodak, Japan).
Histological analysis of the liver
After eight weeks of intervention, the rats were sacri-
ficed and their livers were fixed by 10% buffered forma-
lin and embedded in paraffin. The liver sections (5 μm)
were stained with hematoxylin and eosin (H&E), and
the steatoic degrees of individual liver samples were
examined and scored, according to the percentage of
hepatocytes containing lipid droplets [30] by a patholo-
gist in a blinded manner.
Statistical analysis
Values were expressed as mean ± SD. The difference
among groups was analyzed by one-way ANOVA and
Students t-test. The association among variants was ana-
lyzed by the least significant difference (LSD) test using
the SPSS 13.0 software. The accepted level of signifi-
cance was p < 0.05.
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